Any current/future new fundraising through debt or equity?

Kopran Limited does not intend to take any additional debt for capex requirements in the near term. The company is not looking at very heavy capex in the next one year. The next major capex is expected at the Panoli plant once environmental clearance is obtained and after the plant runs for about one year. Expansion over the next 3-4 years can be done at existing facilities without acquiring new land parcels. There was no mention of any current or future fundraising plans through equity in the provided transcript.

Any current/future capex/capital investment/strategic investment?

No intention to take additional debt for capex; internal cash flows are expected to suffice for near-term investments. No heavy capex planned in the next one year. Next major capex will be at Panoli site, post-environment clearance, expected likely next fiscal. For next 3-4 years, existing facilities including Panoli can support expansions without needing new land or greenfield projects. Panoli plant commissioning is expected around Q3 FY25, with initial commercial production slated after environmental clearance. R&D center at Panoli is already established; full-scale activity will b

Future growth expectations in sales/revenue/volumes?

Kopran Limited expects meaningful margin increase and growth from FY'25-26 onwards due to integration of intermediates and new product launches, including US ethanol exports. Sales growth of around 18% to 20% is targeted for FY'25 without considering Panoli operations, aiming for INR730-740 crores in sales and INR100 crores in EBITDA. Panoli plant commercial production is expected to start in Q3 FY'25, contributing to future growth though initial revenues may be limited due to validation and vendor approvals. New products like Edoxaban, Lacosamide, Macitentan, and Penems (Faropenem, Erta

Future growth expectations in earnings/operating earnings/profits/EPS?

Kopran Limited expects revenue growth of 18% to 20% in FY25, translating to sales around INR 730-740 crores and EBITDA near INR 100 crores. A meaningful improvement in margins and earnings is anticipated from FY25-26 onwards due to integration of intermediates and exports of higher-margin products. New product launches and international approvals (including US and EU markets) are expected to enhance profitability. Panoli plant commercial production is anticipated to start in Q3 FY25, with EBITDA breakeven visibility expected closer to operation start. Long-term EBITDA margin guidance is 18%-20

Kopran LtdQ4 FY24Pharmaceuticals & Biotechnology

Kopran Ltd Q4 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹282P/E: 55.0Market Cap: ₹1.4K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 3

Margin

Category 1

Fundraise

Order

N/A

Capex

Yes

2 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 3

Kopran Limited expects meaningful margin increase and growth from FY'25-26 onwards due to integration of intermediates and new product launches, including US ethanol exports.
Sales growth of around 18% to 20% is targeted for FY'25 without considering Panoli operations, aiming for INR730-740 crores in sales and INR100 crores in EBITDA.
Panoli plant commercial production is expected to start in Q3 FY'25, contributing to future growth though initial revenues may be limited due to validation and vendor approvals.
New products like Edoxaban, Lacosamide, Macitentan, and Penems (Faropenem, Ertapenem) are expected to boost growth.
Expansion plans include increasing regulated market presence (US, Europe, UK registrations) which have better margin profiles than domestic and African markets.
CDMO business growth is expected after regulatory approvals, possibly starting in 1-2 years.
Long-term aspiration is 18%-20% EBITDA margin driven by new high-margin products and export market penetration.

Margin guidance

Category 1

Kopran Limited expects revenue growth of 18% to 20% in FY25, translating to sales around INR 730-740 crores and EBITDA near INR 100 crores.
A meaningful improvement in margins and earnings is anticipated from FY25-26 onwards due to integration of intermediates and exports of higher-margin products.
New product launches and international approvals (including US and EU markets) are expected to enhance profitability.
Panoli plant commercial production is anticipated to start in Q3 FY25, with EBITDA breakeven visibility expected closer to operation start.
Long-term EBITDA margin guidance is 18%-20%, with margins improving as international vendor approvals come through.
Internal cash flows from operations are expected to fund capex, with no significant new debt planned.
Overall, the company is confident of sustained growth and margin expansion over the coming years.

See what Kopran Ltd management said on margin guidance — free account, 30 seconds.

Fundraise plans

Kopran Limited does not intend to take any additional debt for capex requirements in the near term.
The company is not looking at very heavy capex in the next one year.
The next major capex is expected at the Panoli plant once environmental clearance is obtained and after the plant runs for about one year.
Expansion over the next 3-4 years can be done at existing facilities without acquiring new land parcels.
There was no mention of any current or future fundraising plans through equity in the provided transcript.

Order book

- The transcript and presentation do not explicitly mention the current or expected order book or pending orders for Kopran Limited. - Discussions focus more on revenue, EBITDA, new product launches, and approvals in regulated markets. - Key points indicate upcoming commercial orders expected within the next 3 to 6 months, particularly for US ethanol and European nitroxylin products. - Supply of ethanol to a large US multinational is anticipated to ramp up shortly post-validation and regulatory approvals. - No specific quantified details about order book size or backlog are provided in the available sections. - The management states confidence in growth driven by new product commercialization and geographic diversification, potentially impacting future order inflows positively. Hence, explicit current or pending order book data is not disclosed in this document.

See what Kopran Ltd management said on order book — free account, 30 seconds.

Capex plans

Yes

No intention to take additional debt for capex; internal cash flows are expected to suffice for near-term investments.
No heavy capex planned in the next one year.
Next major capex will be at Panoli site, post-environment clearance, expected likely next fiscal.
For next 3-4 years, existing facilities including Panoli can support expansions without needing new land or greenfield projects.
Panoli plant commissioning is expected around Q3 FY25, with initial commercial production slated after environmental clearance.
R&D center at Panoli is already established; full-scale activity will begin after environmental clearance is obtained.
Future CDMO expansion may occur in 1-2 years after approvals.
Further brownfield expansions may be made at current sites after Panoli runs for a year.

Track Kopran Ltd — get its next earnings analysis in your feed

How does Kopran Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

ThisKopran Ltd

Rev 3Mar 1

See where Kopran Ltd sits in Pharmaceuticals & BiotechnologySee which companies these are, and every other name in the sector.Open rankings

How does Kopran Ltd rank in Pharmaceuticals & Biotechnology?

Compare Kopran Ltd against every Pharmaceuticals & Biotechnology company (Q4 FY24) on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

What Kopran Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

Natural Capsules Ltd (Q1 FY27)
Revenue from Operations for Q1FY27: ₹48.71 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q1 FY27 investor presentation — and how it ra
Aptus Pharma Ltd (Q4 FY26)
The investor presentation reports quarterly revenue of ₹40.36 crore for Q4 FY2026. Key concall takeaways from Aptus Pharma Ltd's Q4 FY26 earnings call — and…
Aptus Pharma Ltd (Q1 FY27)
Revenue from Operations for H2 FY26: ₹32.20 crore, up 117.5% YoY from ₹14.80 crore in H2 FY25 (Page 23) . Key concall takeaways from Aptus Pharma Ltd's Q1 FY27…
RPG Life Sciences Ltd (Q2 FY25)
Q2 FY25: ₹172.2 Crores . Key concall takeaways from RPG Life Sciences Ltd's Q2 FY25 earnings call — and how it ranks against sector peers.

Compare:vs Sun Pharma.Inds.vs Divis Laboratories Ltd vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →